ProCE Banner Activity

FAQs: Clinical Challenges With BTK Inhibitors or Venetoclax-Based Therapy for Patients With CLL

Clinical Thought

In this brief commentary, 2 expert pharmacists answer frequently asked questions on the use of BTK inhibitors and venetoclax-based therapy for patients with CLL.

Released: March 13, 2023

Expiration: March 11, 2024

Share

Provided by

ProCE Banner

Supporters

This activity is supported by educational grants from

AstraZeneca

Genentech, a member of the Roche Group

Disclosure

Victoria Nachar, PharmD, BCOP: consultant/advisor/speaker: ADC Therapeutics, Genmab.

Caitlin Rausch, PharmD, BCOP, has no relevant financial relationships to disclose.